AR056861A1 - Compuestos triciclicos fusionados como inhibidores de la necrosis tumoral. composiciones farmaceuticas y procesos de obtencion - Google Patents
Compuestos triciclicos fusionados como inhibidores de la necrosis tumoral. composiciones farmaceuticas y procesos de obtencionInfo
- Publication number
- AR056861A1 AR056861A1 ARP050104716A ARP050104716A AR056861A1 AR 056861 A1 AR056861 A1 AR 056861A1 AR P050104716 A ARP050104716 A AR P050104716A AR P050104716 A ARP050104716 A AR P050104716A AR 056861 A1 AR056861 A1 AR 056861A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- aryl
- heterocyclyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Abstract
Procesos de obtencion y composiciones farmacéuticas que los comprenden. Reivindicacion 1: Un compuesto del la formula general (1), en donde R1, R2, R3, R4, R5, R6 y R8 se seleccionan independientemente de hidrogeno, halogeno, hidroxi, alquilo, alquenilo, cicloalquilo, alcoxi, ciano, nitro, trifluorometilo, arilo, heterociclilo, heteroarilo, alquilsulfonilo, heterociclilsulfonilo, heteroarisulfonilo, -S(O)2-NH-heterociclilo, -S(O)2-NH-heteroarilo , sulfonamida, -S(O)2-NH-alquilo, -S(O)2-NH- cicloalquilo, -S(O)2-NH-arilo, -NH-S(O)2-alquilo, -NH-S(O)2-cicloalquilo, -NH-S(O)2-arilo, -NH-S(O)2-heterociclilo, -NH-S(O)2-heteroarilo, (CH2)nC(O)R9, NR11R12, hidrazina y N=R'; R7 es alquilo, -(CH2)nC(O)R9 o -C(O)NR11R12; R9 es hidrogeno, halogeno, alquilo, cicloalquilo, trifluorometilo, OR10, arilo o heterociclilo; R10 es hidrogeno, alquilo, cicloalquilo, trifluorometilo, arilo o heterociclilo; R11 y R12 se seleccionan independientemente de: hidrogeno, alquilo, cicloalquilo, alquilamino, arilo, heteroarilo, heterociclilo, -(CH2)nC(O)R9 y cicloalquilaminoalquilcarbonilo; o R11 y R12, junto con el átomo N al cual están unidos, forman un heterociclilo de 5, 6, 7 u 8 miembros, opcionalmente tienen uno o más hetero-átomos adicionales seleccionados de: O, N y S; R' es heterociclilo o cicloalquilo; n es 0, 1 o 2; en donde el alquilo o el cicloalquilo se sustituyen o no por uno o dos del mismo o de distintos grupos seleccionados de: halogeno, hidroxi, alquilcarboxi, amino, cicloalquilo, alcoxi ariloxi, alcoxilcarbonilo, arilalcoxicarbonilo, aminocarbonilo, alquilamino, dialquilamino, cicloalquilamino, cicloalquil alquilamino, heterociclilo alquilamino, heteroarilo, heteroarilamino, heteroarilalquilamino, dialquilamin-alquilamino, arilo, amino arilo, heteroarilo y heterociclilo; el heterociclo se encuentra sustituido o no sustituido por uno o dos del mismo o distintos grupos seleccionados de: halogeno, hidroxi, alcoxi, oxo, alquil cicloalquilo, cicloalquil alquilo, arilo, hidroxialquilo, amino, aminoalquilo, alquilaminoalquilo, heterociclilalquilo, heteroaril alquilo, aralquilo, alquilheteroarilo, cicloalquilheteroarilo, formilo, alquilcarbonilo, alcoxicarbonilo, aril alcoxicarbonilo, cicloalquilcarbonilo, arilcarbonilo, heteroarilcarbonilo, -SH, S-alquilo, -S(O)2-alquilo, -S(O)2-arilo, alquilheteroarilo, cicloalquilheteroarilo, alquilamino y alquilheteroaril amino; el arilo se encuentra sustituido o no sustituido por uno o dos del mismo o de distintos grupos seleccionados de; halogeno, nitro, alquilo, trifluorometilo, alcoxi, amino, mono- o di- alquilamino, heteroarilo alquilo y aralquilo; el heteroarilo se encuentra sustituido o no sustituido por uno o dos del mismo o de distintos grupos seleccionados de halogeno, alquilo, cicloalquilo, nitro y amino; W es S(O)m y m es 0, 1 o 2; en todas sus formas esteroisoméricas y tautoméricas y mezclas del mismo en todos los índices y sus sales y solvatos farmacéuticamente aceptables y polimorfos y prodrogas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1226MU2004 | 2004-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056861A1 true AR056861A1 (es) | 2007-10-31 |
Family
ID=38654748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050104716A AR056861A1 (es) | 2004-11-10 | 2005-11-10 | Compuestos triciclicos fusionados como inhibidores de la necrosis tumoral. composiciones farmaceuticas y procesos de obtencion |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US7834052B2 (es) |
| EP (1) | EP1812419A2 (es) |
| JP (1) | JP2008519824A (es) |
| KR (1) | KR20070106981A (es) |
| CN (1) | CN101076525B (es) |
| AR (1) | AR056861A1 (es) |
| AU (1) | AU2005303410B2 (es) |
| CA (1) | CA2587671A1 (es) |
| IL (2) | IL183038A0 (es) |
| MX (1) | MX2007005470A (es) |
| NZ (1) | NZ554937A (es) |
| RU (1) | RU2406724C2 (es) |
| TW (1) | TW200615273A (es) |
| WO (1) | WO2006051477A2 (es) |
| ZA (1) | ZA200703712B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010111673A1 (en) | 2009-03-27 | 2010-09-30 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic hcv inhibitors |
| CA2772085A1 (en) * | 2009-08-27 | 2011-03-03 | The U.S.A., As Represented By The Secretary, Dept. Of Health And Human S Ervices | Compounds that treat malaria and prevent malaria transmission |
| US8598158B2 (en) | 2009-12-14 | 2013-12-03 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds for the treatment of inflammatory disorders |
| EP2513115B1 (en) * | 2009-12-18 | 2013-10-09 | Basilea Pharmaceutica AG | Tricyclic antibiotics |
| US8822520B2 (en) | 2010-09-22 | 2014-09-02 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
| WO2012050918A2 (en) * | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
| GB201507903D0 (en) * | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
| CN106995382A (zh) * | 2016-01-25 | 2017-08-01 | 济南和润化工科技有限公司 | 一种催化氢化法生产3-甲基-4-氨基苯甲酸的方法 |
| JP6968092B2 (ja) * | 2016-04-01 | 2021-11-17 | ユーシービー バイオファルマ エスアールエル | Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体 |
| JP6968090B2 (ja) * | 2016-04-01 | 2021-11-17 | ユーシービー バイオファルマ エスアールエル | Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体 |
| BR112018069931A2 (pt) * | 2016-04-01 | 2019-02-05 | Sanofi Sa | derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf |
| JP6968089B2 (ja) * | 2016-04-01 | 2021-11-17 | ユーシービー バイオファルマ エスアールエル | Ｔｎｆ活性のモジュレーターとしての縮合六環式イミダゾール誘導体 |
| CN106831460A (zh) * | 2017-02-24 | 2017-06-13 | 青铜峡市嘉华化工有限公司 | 3‑甲基‑4‑氨基苯甲酸的制备方法 |
| USD817148S1 (en) * | 2017-04-05 | 2018-05-08 | Dormakaba Canada Inc. | Locking system housing |
| CN107501106A (zh) * | 2017-08-14 | 2017-12-22 | 中涛新材料有限公司 | 一种催化加氢制备3‑甲基‑4‑氨基苯甲酸的方法 |
| EP3936192A4 (en) | 2019-03-06 | 2022-11-16 | Daiichi Sankyo Company, Limited | PYRROLOPYRAZOL DERIVATIVES |
| CN115010621B (zh) * | 2022-07-21 | 2023-11-03 | 山东百启生物医药有限公司 | 一种4-溴-3-甲基苯甲腈的合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL48807A0 (en) * | 1975-02-18 | 1976-03-31 | Syntex Inc | Novel 6,11-dihydrodibenzo-thiepin-11-ones,their preparation and compositions containing them |
| US4130654A (en) * | 1978-01-30 | 1978-12-19 | Syntex (U.S.A.) Inc. | Novel 4-(8X-6,11-dihydrodibenzo-[b.e.]-thiepin-11-one-3-yl)-4-oxobutyric acids, methods of preparation, compositions and uses thereof |
| IL57077A0 (en) * | 1978-04-21 | 1979-07-25 | Syntex Inc | 6,11-dihydrodibenzo-thiepin-11-one s-oxides their preparation and pharmaceutical compositions containing them |
| GB2094790B (en) | 1981-03-13 | 1985-10-09 | Spofa Vereinigte Pharma Werke | Tricycle compounds |
| JPH0240662A (ja) | 1988-08-01 | 1990-02-09 | Ricoh Co Ltd | 電子写真用感光体 |
| US5036067A (en) * | 1990-03-14 | 1991-07-30 | Merck & Co., Inc. | Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase |
| JPH08119920A (ja) | 1994-10-18 | 1996-05-14 | Kyowa Hakko Kogyo Co Ltd | 三環式アニリド誘導体 |
| US5698551A (en) * | 1995-04-07 | 1997-12-16 | Novo Nordisk A/S | Heterocyclic compounds |
| JPH0940662A (ja) | 1995-05-24 | 1997-02-10 | Kyowa Hakko Kogyo Co Ltd | 三環式化合物 |
| JPH11130772A (ja) | 1997-10-28 | 1999-05-18 | Kyowa Hakko Kogyo Co Ltd | 含窒素複素環化合物 |
| ZA9811898B (en) | 1997-12-29 | 2000-06-28 | Ortho Mcneil Pharm Inc | Anti-Inflammatory Compounds. |
| TW200614995A (en) * | 2004-11-10 | 2006-05-16 | Nicholas Piramal India Ltd | Tricyclic guanidine derivatives as sodium-proton exchange inhibitors |
-
2005
- 2005-10-31 TW TW094138179A patent/TW200615273A/zh unknown
- 2005-11-08 CN CN2005800426605A patent/CN101076525B/zh not_active Expired - Fee Related
- 2005-11-08 NZ NZ554937A patent/NZ554937A/en not_active IP Right Cessation
- 2005-11-08 CA CA002587671A patent/CA2587671A1/en not_active Abandoned
- 2005-11-08 JP JP2007540782A patent/JP2008519824A/ja not_active Ceased
- 2005-11-08 US US11/667,580 patent/US7834052B2/en not_active Expired - Fee Related
- 2005-11-08 EP EP05801266A patent/EP1812419A2/en not_active Withdrawn
- 2005-11-08 WO PCT/IB2005/053654 patent/WO2006051477A2/en active Application Filing
- 2005-11-08 KR KR1020077013140A patent/KR20070106981A/ko not_active Application Discontinuation
- 2005-11-08 MX MX2007005470A patent/MX2007005470A/es active IP Right Grant
- 2005-11-08 AU AU2005303410A patent/AU2005303410B2/en not_active Ceased
- 2005-11-08 RU RU2007121682/04A patent/RU2406724C2/ru not_active IP Right Cessation
- 2005-11-10 AR ARP050104716A patent/AR056861A1/es not_active Application Discontinuation
-
2007
- 2007-05-07 IL IL183038A patent/IL183038A0/en not_active IP Right Cessation
- 2007-05-07 IL IL210036A patent/IL210036A0/en unknown
- 2007-05-08 ZA ZA200703712A patent/ZA200703712B/xx unknown
-
2010
- 2010-08-11 US US12/854,745 patent/US7964631B2/en not_active Expired - Fee Related
- 2010-08-11 US US12/854,761 patent/US8163730B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20100324026A1 (en) | 2010-12-23 |
| US20100305094A1 (en) | 2010-12-02 |
| IL183038A0 (en) | 2007-09-20 |
| US8163730B2 (en) | 2012-04-24 |
| RU2007121682A (ru) | 2008-12-20 |
| MX2007005470A (es) | 2007-07-10 |
| WO2006051477A3 (en) | 2006-08-03 |
| CN101076525A (zh) | 2007-11-21 |
| US20070299050A1 (en) | 2007-12-27 |
| KR20070106981A (ko) | 2007-11-06 |
| AU2005303410B2 (en) | 2011-12-15 |
| TW200615273A (en) | 2006-05-16 |
| ZA200703712B (en) | 2010-04-28 |
| JP2008519824A (ja) | 2008-06-12 |
| EP1812419A2 (en) | 2007-08-01 |
| RU2406724C2 (ru) | 2010-12-20 |
| CA2587671A1 (en) | 2006-05-18 |
| IL210036A0 (en) | 2011-02-28 |
| US7964631B2 (en) | 2011-06-21 |
| US7834052B2 (en) | 2010-11-16 |
| WO2006051477A2 (en) | 2006-05-18 |
| NZ554937A (en) | 2011-01-28 |
| CN101076525B (zh) | 2011-07-27 |
| AU2005303410A1 (en) | 2006-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056861A1 (es) | Compuestos triciclicos fusionados como inhibidores de la necrosis tumoral. composiciones farmaceuticas y procesos de obtencion | |
| AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
| AR082888A1 (es) | Compuestos de piridina para la inhibicion de nampt | |
| AR040076A1 (es) | Derivados de piridazin-3(2h)-ona | |
| AR076002A1 (es) | Derivados imidazolicos heterociclicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden. | |
| AR057989A1 (es) | Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas | |
| AR050691A1 (es) | Compuestos de isoindolona como potenciadores del receptor metabotropico de glutamato. procesos de obtencion y composiciones farmaceuticas. | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| AR067996A1 (es) | Derivados heterociclicos de ciclopropano,composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de afecciones asociadas a receptores de histamina h3, tales como enfermedad de alzheimer y esquizofrenia,entre otros. | |
| AR029090A1 (es) | Derivados pirazol triciclicos | |
| AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
| ES2530431T3 (es) | Compuestos heterocíclicos como moduladores positivos del receptor de glutamato metabotrópico 2 (receptor mGlu2) | |
| AR065280A1 (es) | Agentes antiparasitarios | |
| AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
| AR057296A1 (es) | Diarilsulfona sulfonamidas y el uso de las mismas | |
| AR040595A1 (es) | Derivados de amina sustituida y metodos de uso | |
| AR049696A1 (es) | Derivados de indol | |
| CO6251271A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| AR055171A1 (es) | Derivados de carboxamida como antagonistas del receptor muscarinico | |
| CO5700763A2 (es) | Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra | |
| AR059184A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica | |
| AR047537A1 (es) | Piridazinonaureas como antagonistas de integrinas | |
| AR049276A1 (es) | Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR065249A1 (es) | Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |